구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Praluent (alirocumab) |
Overview Company | Sanofi / Regeneron |
Overview Modality | ANTIBODY |
Overview Target | PCSK9 |
Overview Indication | Hyperlipidemia, ASCVD, HeFH |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Flexible q2w dosing; post-ACS outcomes label |
Positioning Known limitation | resistance to immune checkpoint blockade |
MoA Mechanism | Alirocumab inhibits PCSK9, increasing available LDL receptors and lowering LDL-C similarly to evolocumab. |
MoA Biomarker | LDL-C, ApoB. |
PK/PD Half-life | 12 h |
PK/PD Species | Mouse, LDL-C ↓~58% |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Major finding | Injection-site reactions, flu-like symptoms. |
Toxicology CRS | N/A |
Clinical Safety signal | Injection-site reactions, flu-like symptoms. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Preclinical Animal (cat.) | Mouse |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Praluent (alirocumab) |
Overview Company | Sanofi / Regeneron |
Overview Modality | ANTIBODY |
Overview Target | PCSK9 |
Overview Indication | Hyperlipidemia, ASCVD, HeFH |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Flexible q2w dosing; post-ACS outcomes label |
Positioning Known limitation | resistance to immune checkpoint blockade |
MoA Mechanism | Alirocumab inhibits PCSK9, increasing available LDL receptors and lowering LDL-C similarly to evolocumab. |
MoA Biomarker | LDL-C, ApoB. |
PK/PD Half-life | 12 h |
PK/PD Species | Mouse, LDL-C ↓~58% |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Major finding | Injection-site reactions, flu-like symptoms. |
Toxicology CRS | N/A |
Clinical Safety signal | Injection-site reactions, flu-like symptoms. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Preclinical Animal (cat.) | Mouse |
추천 비교
추천 비교